By Kyle Blankenship
Months into the COVID-19 pandemic, just two therapies have emerged as FDA-approved emergency therapies hospitalized patients. Last month, Eli Lilly rolled out findings for rheumatoid arthritis med Olumiant in an effort to become the third—and new data shows the extent of the drug's effect on improving recovery.
read more
By Heather Landi
Despite the interest in telehealth fueled by the pandemic, virtual care didn't fill in the gap for missed primary care appointments, according to a study published in JAMA Open. Here is why researchers are concerned about the quality of primary care with the telehealth boom.
read more
By Ben Adams
Infectious disease expert Anthony Fauci, M.D., has said of Regeneron’s experimental antibody cocktail that: “There is a reasonably good chance that in fact it made [President Donald Trump] much better.”
read more
By Robert King
CMS alerted providers to major changes to the Medicare advance loan repayment terms, including how financially strapped hospitals can get more time to repay.
read more
By Tina Reed
HCA Healthcare is returning $6 billion in COVID-19 relief funds it received as part of the Coronavirus Aid, Relief, and Economic Security Act earlier this year.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
The FDA said it is tracking over 550 individual drug programs, outside of vaccines, currently making their way through the planning stages for use against COVID-19. Meanwhile, BARDA tapped the CRO Pharm-Olam to join its clinical studies network for medical countermeasures—its second newcomer this week, after PRA Health.
read more
By Arlene Weintraub
A Johns Hopkins team found that blocking the protein factor D prevented the process by which SARS-CoV-2 over-stimulates the immune response, causing the destruction of healthy cells in the lungs, blood vessels and organs. They believe the discovery could inspire new treatments to prevent severe COVID-19 symptoms.
read more
By Tina Reed
The American Medical Association announced new CPT codes for multi-virus tests used to detect COVID-19 and flu with a single test.
read more
By Robert King
Limitations such as strict coding requirements could be why few providers are getting reimbursements for treating uninsured COVID-19 patients.
read more
By Ben Adams
Pharm-Olam has become the latest contract research organization to be added into BARDA’s Clinical Studies Network.
read more
